During the last few years, the prognosis of advanced cutaneous melanoma (CM) has considerably improved due to the development of novel immune checkpoint inhibitor (ICI) therapies, which act to enhance the anti-tumor immune responses of CD8+ lymphocytes [1]. Here, CD8A is linked to neoplasm.